Delving into the Latest Updates on Loncastuximab tesirine with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

Anti-CD19-PBD-conjugate-ADC, Immunoglobulin g1-kappa, anti-(homo sapiens b-lymphocyte antigen cd-19)chimeric monoclonal antibody conjugated to an average of two molecules of tesirine.gamma.1 heavy chain (1-449) (mus musculus vh (ighv1-69*02 (86%) (ighd)-ighj4*01)) (8.8.13) (1-120) -, Lonca

+ [8]

Target

CD19 x DNA

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA modulators(DNA modulators), DNA alkylating agents

+ [1]

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Diffuse large B-cell lymphoma recurrentHigh grade B-cell lymphomaRefractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type+ [17]

Inactive Indication

Burkitt LymphomaMediastinal large B-cell lymphomaPre B-cell acute lymphoblastic leukemia+ [1]

Originator Organization

ADC Therapeutics SA

Active Organization

ADC Therapeutics SA

Swedish Orphan Biovitrum AB

University of Washington

+ [2]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (23 Apr 2021),

B-Cell LymphomaDiffuse Large B-Cell Lymphoma

RegulationConditional marketing approval (EU), Orphan Drug (EU), Priority Review (US), Accelerated Approval (US)

Login to view First Approval Timeline

Structure

Boost your research with our XDC technology data.

login

or

view full example data

Boost your research with our XDC technology data.

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around 30 in every 100 children treated. It is very important that investigators quickly find better medicines for these children and young people.
The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). The investigators are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.
Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then the investigators will take it out of the trial as soon as possible. This will let other new medicines be added to the trial and tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine available.
Children from around the world will be invited to take part in the trial. The investigators will then check on them for at least two years after they finish the trial treatment to look for possible side effects of the new medicine.

Start Date01 May 2024

Sponsor / Collaborator

University of Birmingham

[+3]

NCT05672251 / RecruitingPhase 2IIT

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine. Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving loncastuximab tesirine with mosunetuzumab may help treat patients with relapsed or refractory diffuse large B-cell lymphoma.

Start Date02 Jan 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT05971251 / RecruitingPhase 1IIT

Addition of loNcasTuxImab teSirine to AcalabruTinib in Chronic Lymphocytic Leukemia(Anti-Static Study)

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

Start Date18 Dec 2023

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

100 Clinical Results associated with Loncastuximab tesirine

Login to view more data

100 Translational Medicine associated with Loncastuximab tesirine

Login to view more data

100 Patents (Medical) associated with Loncastuximab tesirine

Login to view more data

56

Literatures (Medical) associated with Loncastuximab tesirine

01 Apr 2024·Haematologica

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.

Article

Author: Zinzani, Pier Luigi ; Stathis, Anastasios ; Radford, John ; Wang, Ying ; Caimi, Paolo F ; Wang, Luqiang ; Solh, Melhem ; Carlo-Stella, Carmelo ; Qin, Yajuan ; Alderuccio, Juan Pablo ; Kahl, Brad S ; Ardeshna, Kirit M ; Hamadani, Mehdi ; Ai, Weiyun Z ; Xu, Zhiying Cindy ; Hess, Brian

Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in the pivotal phase II LOTIS-2 study in heavily pretreated patients with R/R DLBCL. Here we present updated efficacy and safety analyses from LOTIS-2, performed for all patients and in subsets of patients with a complete response (CR), including patients with CR who were event-free (no progressive disease or death) for ≥1 year and ≥2 years from cycle 1, day 1 of treatment. Lonca was administered every 3 weeks (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles). As of the final data cutoff (September 15, 2022; median follow-up: 7.8 months [range, 0.3-42.6]), 70 of 145 (48.3%) patients achieved an overall response. Thirty-six (24.8%) patients achieved CR, of which 16 (44%) and 11 (31%) were event-free for ≥1 year and ≥2 years, respectively. In the all-treated population, the median overall survival was 9.5 months; the median progression-free survival was 4.9 months. Among patients with CR, median overall survival and progression-free survival were not reached, with 24-month overall and progression-free survival rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively. No new safety concerns were detected. With additional follow-up, Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR (clinicaltrials gov. Identifier: NCT03589469).

01 Feb 2024·eJHaem

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

Article

Author: Nickaeen, Masoud ; Hamadani, Mehdi ; Wang, Ying ; Pantano, Serafino ; Zammarchi, Francesca ; Knab, Tim ; Cucchi, Danilo ; Utsey, Kiersten ; Carlo-Stella, Carmelo ; Havenith, Karin ; Caimi, Paolo F. ; Boni, Joseph ; Jordie, Eric

AbstractCD19‐targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]) is a CD19‐targeting antibody‐drug conjugate indicated for R/R DLBCL after at least two systemic treatments. CD19 expression was evaluated in patients receiving Lonca in the LOTIS‐2 clinical trial with available tissue samples obtained after last systemic therapy/before Lonca treatment. Lonca cytotoxicity was evaluated in a panel of six lymphoma cell lines with various CD19 expression levels. Quantitative systems pharmacology (QSP) modelling was used to predict Lonca responses. Lonca responses were seen in patients across all CD19 expression levels, including patients with low/no detectable CD19 expression and H‐scores at baseline. Similarly, Lonca induced cytotoxicity in cell lines with different levels of CD19 expression, including one with very low expression. QSP modelling predicted that CD19 expression by immunohistochemistry alone does not predict Lonca response, whereas inclusion of CD19 surface density improved response prediction. Virtual patients responded to Lonca with estimated CD19 as low as 1000 molecules/cell of CD19, normally below the immunohistochemistry detection level. We found Lonca is an effective treatment for R/R DLBCL regardless of CD19 expression by immunohistochemistry. These results provide the basis for future studies addressing CD19‐targeted agent sequencing.

01 Feb 2024·Bone Marrow Transplantation

Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

Article

Author: Maakaron, Joseph E ; Fijalka, Andrew ; Craver, Emily ; Khurana, Arushi ; Li, Zhuo ; Epperla, Narendranath ; Bhaskar, Shakthi T ; Annunzio, Kaitlin ; Jagadeesh, Deepa ; Chavez, Julio ; Iqbal, Madiha ; Isufi, Iris ; Dholaria, Bhagirathbhai R ; Lin, Yi ; Kharfan-Dabaja, Mohamed A ; Rosenthal, Allison ; Mishra, Rahul ; Sandoval-Sus, Jose D ; Awan, Farrukh T ; Sumransub, Nuttavut ; Saha, Aditi ; Ivanov, Stanislav A

Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1-199) weeks from CAR-T infusion. Median number of systemic therapies pre-CAR-T therapy was 3 (range: 1-6); axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2-38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0-5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1-56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.

124

News (Medical) associated with Loncastuximab tesirine

09 May 2024

·www.biospace.com

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the decrease in total operating expenses for 2024, the expected cash runway into mid-2026, the effectiveness of the new commercial go-to-market strategy, competition from new technologies, and the Company’s ability to grow ZYNLONTA® revenue in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; approval by the NMPA of the BLA for ZYNLONTA® in China submitted by Overland ADCT BioPharma and future revenue from the same, our strategic partners’, including Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the timing and future success from the University of Miami’s IITs in FL and MZL; the timing and results of the Company’s or its partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as the Company’s early-stage pipeline research projects, actions by the FDA or foreign regulatory authorities with respect to the Company’s products or product candidates; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Oaktree and Blue Owl facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. CONTACT: Investors and Media Nicole Riley ADC Therapeutics Nicole.Riley@adctherapeutics.com +1 862-926-9040

Drug ApprovalADCAccelerated Approval

07 May 2024

·www.biospace.com

ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8%

Pictured: 3D illustrations of antibody-drug conjugates carrying their toxic payloads/iStock, Love Employee ADC Therapeutics on Monday released topline Phase II data for its anti-CD19 antibody drug conjugate Zynlonta (loncastuximab tesirine-lpyl), which elicited high rates of treatment response in patients with relapsed or refractory marginal zone lymphoma. Monday’s early data come from 15 evaluable patients out of the total 50 enrolled participants in ADC Therapeutics’ single-arm, open-label mid-stage study. Thirteen of these patients showed complete response (CR) to Zynlonta, while one other patient demonstrated partial response. All treatment responses were maintained until the time of data cut-off. As for safety, Zynlonta was generally well-tolerated and its adverse event pro consistent with what had been established in prior studies. Two patients dropped out of the study due to toxicities, though these “full resolved” once Zynlonta treatment was discontinued, according to the biotech’s news release. Both of those patients remain in CR. With these data in hand, and as long as readouts continue to be positive, ADC Therapeutics plans to “potentially pursue a regulatory pathway and compendia in parallel,” CMO Mohamed Zaki said in a statement. Concurrent with Monday’s readout, the biotech announced that it was putting up for sale more than 13.4 million of its common shares at $4.90 apiece. The company is offering pre-funded warrants to purchase over 8.1 million common shares at $4.812 per pre-funded warrant. In total, ADC Therapeutics is looking to make around $105 million in gross proceeds. Zynlonta is an antibody-drug conjugate (ADC) designed to target the CD19 surface protein, which is typically found on B cells and is a well-validated target in related malignancies. Once bound to its target, Zynlonta is internalized by the cancer cell and releases its toxic pyrrolobenzodiazepine payload, which in turn targets the DNA and ultimately triggers cell death. The ADC won the FDA’s accelerated approval in April 2021 for the treatment of patients with relapsed or refractory large B-cell lymphoma who had undergone at least two prior lines of systemic therapy. The approval also includes certain types of diffuse large B-cell lymphoma. In July 2023, ADC Therapeutics discontinued the Phase II LOTIS-9 trial of Zynlonta in previously untreated, difficult-to-treat diffuse large B-cell lymphoma after seven patient deaths. Sales for Zynlonta have been largely disappointing. In 2023, the ADC brought in $69.1 million, down from $75 million in 2022. The biotech also reported its first-quarter earnings on Monday, posting that Zynlonta’s sales dropped to $17.85 million from nearly $19 million during the same period in 2023. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical ResultDrug ApprovalPhase 2Accelerated ApprovalADC

06 May 2024

·www.fiercepharma.com

ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale

Zynlonta generated $17.8 million in the first quarter of 2024, a 7% increase from the last quarter of 2023. But the result represented a year-over-year decline from $19 million in 2023. In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initiated study in marginal zone lymphoma (MZL). First, the study results. In a release, ADC said that among 15 patients with relapsed or refractory MZL who were treated with Zynlonta, 13 achieved a complete response and one achieved a partial response. The result comes from a single-arm, open-label study testing six cycles of the drug over 18 weeks. Patients must have tried at least one prior line of systemic therapy to be eligible for enrollment, ADC explained in the release. As of a March 30 data cutoff, 15 patients could be evaluated. With the initial findings in hand, the research team plans to expand "the number of sites to accelerate enrollment in this trial," lead investigator Izidore Lossos, M.D., said in a statement. "Achievement of complete response to treatment represents the strongest predictor of positive outcomes in MZL so these initial results are encouraging,” Lossos said. The trial is currently underway at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope. ADC is tracking the study findings and plans to "potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available," Chief Medical Officer Mohamed Zaki, M.D., Ph.D., said in a statement. Zynlonta is a CD19-targeted antibody-drug conjugate currently approved to treat adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The drug generated $17.8 million in the first quarter of 2024, a year-over-year decline of 6%, ADC said in an earnings release on Monday. The drug is struggling to gain momentum against more efficacious CD19 CAR-T therapies such as Gilead Sciences' Yescarta. Meanwhile, ADC also revealed an agreement to sell $105 million worth of common shares and pre-funded warrants. The company's share price fell 9% after all of Monday's updates.

Clinical ResultADCDrug ApprovalFinancial Statement

100 Deals associated with Loncastuximab tesirine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11338	-	L01XC	DB16222

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diffuse large B-cell lymphoma recurrent	EU	Swedish Orphan Biovitrum AB	20 Dec 2022
Diffuse large B-cell lymphoma recurrent	LI	Swedish Orphan Biovitrum AB	20 Dec 2022
Diffuse large B-cell lymphoma recurrent	NO	Swedish Orphan Biovitrum AB	20 Dec 2022
Diffuse large B-cell lymphoma recurrent	IS	Swedish Orphan Biovitrum AB	20 Dec 2022
High grade B-cell lymphoma	LI	Swedish Orphan Biovitrum AB	20 Dec 2022
High grade B-cell lymphoma	IS	Swedish Orphan Biovitrum AB	20 Dec 2022
High grade B-cell lymphoma	NO	Swedish Orphan Biovitrum AB	20 Dec 2022
High grade B-cell lymphoma	EU	Swedish Orphan Biovitrum AB	20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	NO	Swedish Orphan Biovitrum AB	20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	IS	Swedish Orphan Biovitrum AB	20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	EU	Swedish Orphan Biovitrum AB	20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	LI	Swedish Orphan Biovitrum AB	20 Dec 2022
B-Cell Lymphoma	US	ADC Therapeutics SA	23 Apr 2021
Diffuse Large B-Cell Lymphoma	US	ADC Therapeutics SA	23 Apr 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Large B-cell lymphoma	NDA/BLA	CN	ADC Therapeutics SA	08 Jun 2023
Large B-cell lymphoma	NDA/BLA	CN	Overland PharmaceuticalsStartup	08 Jun 2023
Diffuse large B-cell lymphoma recurrent	Phase 3	JP	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	BR	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	NL	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	FR	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	CH	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	US	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	BE	ADC Therapeutics SA	16 Sep 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	MX	ADC Therapeutics SA	16 Sep 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02669017 (Pubmed \| Circulation) Manual	Phase 1	B-cell lymphoma refractory	183	loncastuximab tesirine	(qdebvluyek) = 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks iscevgebff (jrranrhliz ) View more	Positive	13 May 2021
NCT03589469 (LOTIS-2, Pubmed \| Lancet Oncol) Manual	Phase 2	Diffuse Large B-Cell Lymphoma	145	Loncastuximab tesirine	(jqwnewwler) = bcvxwrpgzx zdjfdaugcf (vhrjsnxzng, 39.9 - 56.7) View more	Positive	01 Jun 2021
GlobeNewswire Manual	Not Applicable	Follicular Lymphoma	-	ZYNLONTA + rituximab	(vqgcjpiwvl) = pfbtbnghgw barzvfsscb (xxezxkbjyj ) View more	Positive	04 Jan 2024
LOTIS-7 (GlobeNewswire) Manual	Phase 1	Follicular Lymphoma \| Diffuse Large B-Cell Lymphoma \| Marginal Zone B-Cell Lymphoma	-	mosunetuzumab or glofitamab+ZYNLONTA	(ojwiqheali) = The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 µg/kg in both arms, cstdranmqk (snhmkwfxbe )	Positive	04 Jan 2024
ChiCTR2300072058 (ASH2023) Manual	Phase 2	Diffuse Large B-Cell Lymphoma	64	Loncastuximab Tesirine	(fcyycpfjem) = dcxauxloxu jhljtktevr (ixhpgebhqp, 38.7 - 64.2) View more	Positive	11 Dec 2023
NCT02669017 (Pubmed \| Clin Cancer Res) Manual	Phase 1	B-Cell Lymphoma	88	ADCT-402	(fevhpagndz) = ioorkfycgq pcjmwhrzet (wssxjofvmm ) View more	Positive	01 Dec 2019
NCT03684694 (Corporate Publications) Manual	Phase 1	Non-Hodgkin Lymphoma	37	LONCASTUXIMAB TESIRINE+IBRUTINIB	(fnpdonufcn) = qqbolcadyt kycxzxadmn (lpmajgcscx ) View more	Positive	17 Jun 2021
NCT05296070 (Biospace) Manual	Phase 2	Marginal zone lymphoma refractory	50	Zynlonta	(dxtlgekifj) = acogkbmapt pulkluckcn (xinphscnle )	Positive	07 May 2024
NCT03589469 (LOTIS-2, Pubmed)	Phase 2	Diffuse Large B-Cell Lymphoma CD19	145	Loncastuximab tesirine	(ifegfzjxdy) = qdslxfkvhf vhifydznue (kaqclouwxw, 50.0 - 81.0) View more	-	01 Apr 2024
NCT02669264 (Pubmed \| Blood Adv) Manual	Phase 1	Refractory B Acute Lymphoblastic Leukemia	35	Loncastuximab tesirine	(rdmypstjyn) = khidyzlfhe rxoxgrjrqr (mapqctnrgi ) View more	-	11 Feb 2020